{"id":11349,"date":"2021-10-26T14:46:26","date_gmt":"2021-10-26T12:46:26","guid":{"rendered":"https:\/\/www.maiwald.eu\/?post_type=publikationen&#038;p=11349"},"modified":"2022-12-27T13:29:03","modified_gmt":"2022-12-27T12:29:03","slug":"article-in-the-current-issue-of-pharma-recht-specialist-journal-for-pharmaceutical-law","status":"publish","type":"publikationen","link":"https:\/\/www.maiwald.eu\/en\/publications\/article-in-the-current-issue-of-pharma-recht-specialist-journal-for-pharmaceutical-law\/","title":{"rendered":"Admissibility of non-challenge clauses and pay-for-delay agreements in settlements and license, 2021"},"content":{"rendered":"\n<p>by Dr <a href=\"https:\/\/www.maiwald.eu\/en\/team\/marco-stief\/\">Marco Stief<\/a><\/p>\n\n\n\n<p>In the current October issue of Pharma Recht &#8211; a specialist journal for pharmaceutical law our partner Dr. Marco Stief has written an article with the equally complex and practically relevant topic &#8220;Admissibility of non-challenge clauses and pay-for-delay agreements in settlements and license agreements&#8221;.<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-11349","publikationen","type-publikationen","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.maiwald.eu\/en\/wp-json\/wp\/v2\/publikationen\/11349","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.maiwald.eu\/en\/wp-json\/wp\/v2\/publikationen"}],"about":[{"href":"https:\/\/www.maiwald.eu\/en\/wp-json\/wp\/v2\/types\/publikationen"}],"version-history":[{"count":8,"href":"https:\/\/www.maiwald.eu\/en\/wp-json\/wp\/v2\/publikationen\/11349\/revisions"}],"predecessor-version":[{"id":16550,"href":"https:\/\/www.maiwald.eu\/en\/wp-json\/wp\/v2\/publikationen\/11349\/revisions\/16550"}],"wp:attachment":[{"href":"https:\/\/www.maiwald.eu\/en\/wp-json\/wp\/v2\/media?parent=11349"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}